LAURA FERGUSON: Open Payments
NPI 1154791028 · COLUMBUS, MS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,729 in 160 payments from 20 companies in 2025. Trend: 2023 $1,321 · 2024 $1,571 · 2025 $2,729
Food & beverage: $2,727Education: $2
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 32 | $649 |
| GlaxoSmithKline, LLC. | 32 | $472 |
| GENZYME CORPORATION | 14 | $242 |
| Verona Pharma, Inc. | 21 | $235 |
| Grifols USA, LLC | 11 | $233 |
| Viatris Specialty LLC | 11 | $153 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $142 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 4 | $87 |
| Amgen Inc. | 5 | $84 |
| Regeneron Healthcare Solutions, Inc. | 3 | $69 |
Products named: DUPIXENT, NUCALA, AIRSUPRA, FASENRA, Ohtuvayre, Prolastin-C Liquid, TRELEGY ELLIPTA, TEZSPIRE.
Industry payments across MS — which companies pay providers there.
